喜炎平注射液不良反应严重程度危险因素:倾向性评分匹配分析
该研究基于2004至2017年中国国家药品不良反应监测信息系统中的26,317例喜炎平注射液相关不良反应病例,分析年龄、体重、给药途径及合并用药等因素与不良反应严重程度的关系。单因素和多因素分析显示,年龄和喜炎平与利巴韦林联用是严重不良反应的独立危险因素,倾向性评分匹配后联用利巴韦林组严重程度升高(p=0.020)。提示应关注老年患者用药安全并减少喜炎平与利巴韦林的联用。
要点
- 年龄是喜炎平注射液严重不良反应的独立危险因素(p<0.001)。
- 喜炎平与利巴韦林联用可增加不良反应严重程度(p=0.020)。
- 老年患者使用喜炎平注射液时应加强安全性监测。
核心结论
- 年龄和喜炎平与利巴韦林联用可能是喜炎平注射液相关不良反应严重程度的潜在危险因素。
研究设计与样本
- 基于中国国家药品不良反应监测信息系统2004至2017年26,317例喜炎平注射液相关不良反应病例的回顾性分析,最终纳入24,911例一般不良反应和1,406例严重不良反应,采用单因素、多因素分析及倾向性评分匹配。
主要发现
- 单因素分析显示年龄(p<0.001)、体重(p<0.001)、给药途径(p=0.008)及喜炎平联用利巴韦林(p=0.031)与不良反应严重程度相关。
- 多因素分析显示喜炎平联用利巴韦林(p=0.048)和年龄(p<0.001)为独立危险因素。
- 倾向性评分匹配后,喜炎平联用利巴韦林组的不良反应严重程度升高(p=0.020)。
关键数值与推荐
- 共纳入24,911例一般不良反应和1,406例严重不良反应。
- 年龄在单因素和多因素分析中均与严重不良反应显著相关(p<0.001)。
- 喜炎平联用利巴韦林在多因素分析中p=0.048,倾向性评分匹配后p=0.020。
临床怎么用
- 临床使用喜炎平注射液时应特别关注老年患者的用药安全。
- 应尽量减少喜炎平与利巴韦林的联用,以降低严重不良反应风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Xiyanping injection (XYP), extraction of Andrographis paniculate (Andrographis paniculata (Burm. f.) Nees, chuan xin lian), is a Chinese patent medicine approved to treat bronchitis in China. In 2017, safety incidents associated with treatment of XYP began to emerge throughout China. However, the risk factors of severity of adverse reactions by XYP remain uncertain. AIM OF THE STUDY: To determine risk factors for the severity of XYP-associated adverse drug reactions (ADRs). MATERIALS AND METHODS: We analyzed a total of 26,317 cases of ADRs linked to the use of XYP injection in the China National Adverse Drug Reaction Monitoring Information System from 2004 to 2017. Data were analyzed with respect to age, gender, ethnicity, previous ADRs, family history of ADRs, dosage specification, medication frequency specification, body weight, route of administration, herb-drug interactions (ribavirin, cefatriaxone, penicillin sodium, ambroxol hydrochloride, clindamycin, cefoxitin sodium, azithromycin, ceftazidime, amoxicillin sodium and clavulanate potassium, levofloxacin, cefazolin sodium pentahydrate, acyclovir) by univariate analysis and multivariate analysis. Propensity score matching was used to compare severity of (general or serious) ADRs. RESULTS: We included 24,911 cases of general ADRs and 1406 cases of serious ADRs. Univariate analysis identified age (p < 0.001), body weight (p < 0.001), route of administration (p = 0.008), co-administration of XYP with ribavirin (p = 0.031) as risk factors of severity of ADRs. Multivariate analysis identified XYP + ribavirin combination (p = 0.048) and age (p < 0.001) as the independent risk factors. Upon propensity score matching, the variables were relatively balanced amongst the two groups of patients with general or severe ADRs, and the level of severity in patients who received treatment of XYP + ribavirin increased (p = 0.020). CONCLUSIONS: Age and co-administration of ribavirin may be potential risk factors for the severity of XYP-associated ADRs. This reminds us to pay more attention to the safety of elderly medication. Minimizing the herb-drug-interaction effects of XYP and ribavirin is a viable treatment target for healthcare professionals in managing serious ADRs amongst patients receiving XYP injection.
引用
- Zheng R, Tao L, Kwong JSW, et al. Risk factors associated with the severity of adverse drug reactions by Xiyanping injection: A propensity score-matched analysis. J Ethnopharmacol. 2019. PMID: 31765765. doi:10.1016/j.jep.2019.112424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。